Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that the humanized anti-soluble aggregated amyloid-beta (A?) monoclonal antibody "LEQEMBI®" has been ...

Cambridge, Massachusetts-based Biogen Inc. ( BIIB) discovers, develops, manufactures, and delivers therapies for treating ...

We’ve debated immigration since Native Americans encountered a group of migrants from England who decided to settle in ...

Sage Therapeutics discontinued development of its lead candidate dalzanemdor after a third clinical failure, leading analysts ...

Opuviz, which references Regeneron Pharmacueticals’ vision loss inhibitor Eylea, treats wet age-related macular degeneration, ...

INCHEON, South Korea and CAMBRIDGE, MA, USA I November 18, 2024 I Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the European ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

State Treasurer Deb Goldberg, Commissioner Jeffrey McCue of MA Department of Transitional Assistance, Suffolk County District Attorney Kevin Hayden, as well as several other state and local officials ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

The Greater Boston Food Bank (GBFB), the largest hunger-relief organization in New England, held its 19th annual Chain of Giving event, an annual tradition uniting elected officials, local advocates, ...

The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement ...